Seamus Kent

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/1099977/publications.pdf

Version: 2024-02-01

623734 713466 21 841 14 21 h-index citations g-index papers 21 21 21 1775 citing authors all docs docs citations times ranked

#	Article	IF	CITATIONS
1	The clinical and cost-effectiveness of total versus partial knee replacement in patients with medial compartment osteoarthritis (TOPKAT): 5-year outcomes of a randomised controlled trial. Lancet, The, 2019, 394, 746-756.	13.7	195
2	Risk of hydroxychloroquine alone and in combination with azithromycin in the treatment of rheumatoid arthritis: a multinational, retrospective study. Lancet Rheumatology, The, 2020, 2, e698-e711.	3.9	117
3	Body mass index and healthcare costs: a systematic literature review of individual participant data studies. Obesity Reviews, 2017, 18, 869-879.	6.5	91
4	What is the impact of chronic kidney disease stage and cardiovascular disease on the annual cost of hospital care in moderate-to-severe kidney disease?. BMC Nephrology, 2015, 16, 65.	1.8	82
5	Outpatient physiotherapy versus home-based rehabilitation for patients at risk of poor outcomes after knee arthroplasty: CORKA RCT. Health Technology Assessment, 2020, 24, 1-116.	2.8	62
6	Common Problems, Common Data Model Solutions: Evidence Generation for Health Technology Assessment. Pharmacoeconomics, 2021, 39, 275-285.	3.3	42
7	Hospital costs in relation to body-mass index in $1\hat{A}\cdot 1$ million women in England: a prospective cohort study. Lancet Public Health, The, 2017, 2, e214-e222.	10.0	30
8	The Challenge of Transparency and Validation in Health Economic Decision Modelling: A View from Mount Hood. Pharmacoeconomics, 2019, 37, 1305-1312.	3.3	28
9	Total versus partial knee replacement in patients with medial compartment knee osteoarthritis: the TOPKAT RCT. Health Technology Assessment, 2020, 24, 1-98.	2.8	27
10	Mapping from the Parkinson's Disease Questionnaire PDQ-39 to the Generic EuroQol EQ-5D-3L. Medical Decision Making, 2015, 35, 902-911.	2.4	26
11	A policy model of cardiovascular disease in moderate-to-advanced chronic kidney disease. Heart, 2017, 103, 1880-1890.	2.9	21
12	Is Doctor Referral to a Lowâ€Energy Total Diet Replacement Program Costâ€Effective for the Routine Treatment of Obesity?. Obesity, 2019, 27, 391-398.	3.0	20
13	Cost-effectiveness of Simvastatin plus Ezetimibe for Cardiovascular Prevention in CKD: Results of the StudyÂofÂHeartÂand Renal Protection (SHARP). American Journal of Kidney Diseases, 2016, 67, 576-584.	1.9	19
14	The use of nonrandomized evidence to estimate treatment effects in health technology assessment. Journal of Comparative Effectiveness Research, 2021, 10, 1035-1043.	1.4	18
15	ARE VALUE OF INFORMATION METHODS READY FOR PRIME TIME? AN APPLICATION TO ALTERNATIVE TREATMENT STRATEGIES FOR NSTEMI PATIENTS. International Journal of Technology Assessment in Health Care, 2013, 29, 435-442.	0.5	16
16	Cost-effectiveness of lipid lowering with statins and ezetimibe in chronic kidney disease. Kidney International, 2019, 96, 170-179.	5.2	13
17	Body mass index and use and costs of primary care services among women aged 55–79 years in England: a cohort and linked data study. International Journal of Obesity, 2019, 43, 1839-1848.	3.4	11
18	BMI and Causeâ€Specific Hospital Admissions and Costs: The UK Biobank Cohort Study. Obesity, 2020, 28, 1332-1341.	3.0	9

SEAMUS KENT

#	Article	IF	CITATION
19	Effects of Vascular and Nonvascular Adverse Events and of Extended-Release Niacin With Laropiprant on Health and Healthcare Costs. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 348-354.	2.2	8
20	Application of quantitative bias analysis for unmeasured confounding in cost–effectiveness modelling. Journal of Comparative Effectiveness Research, 2022, 11, 861-870.	1.4	4
21	Does bariatric surgery reduce future hospital costs? A propensity score-matched analysis using UK Biobank Study data. International Journal of Obesity, 2021, 45, 2205-2213.	3.4	2